Saurabh Dang, MD
Interventional Pain Medicine · Edgewater, NJNPI 1619267374
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Boston Scientific at 57.1% of the total. Reporting peaked in 2021 at $36,102 and has fallen 63.6% since, to $13,148 in 2025. Among interventional pain medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 644 payments — averaging $243.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$89K
- Medtronic$46K
- Abbott$7K
- Saluda Medical Americas, Inc.$4K
- Biotronik NRO, Inc.$2K
- Nevro Corp.$1K
- plus $7K from 37 others
Across 39 payments — averaging $1707.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$48K
- Medtronic$12K
- Saluda Medical Americas, Inc.$8K
Across 2 payments — averaging $24,570 each. An ownership or investment interest held by the physician or an immediate family member.
- Happe Spine$49K
What the payments were for
- Consulting fees$31,88720%
- Speaking & faculty fees$86,46355%
- Travel & lodging$10,6007%
- Food & beverage$27,60018%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPECTRA WAVEWRITER$20,387
- WAVEWRITER ALPHA$16,400
- WaveWriter Alpha Prime 16$14,880
- GENERAL PAIN MANAGEMENT$13,389
- INTELLIS ADAPTIVESTIM$11,822
- INTELLIS$11,647
- GENERAL - THERAPIES$9,984
- Neuromodulation Dspsbls and Accs$4,912
- RESTORESENSORSURESCAN$3,000
- Evoke SCS$2,434
- ADAPTIVESTIM$2,380
- RESTORE$2,280
- SYNCHROMED$2,028
- SYNCHROMEDII$1,935
- ClosureFast$1,622
- Prospera$1,333
- INFINION$1,200
- Proclaim IPG$967
- Intracept$879
- Prometra II$871
How this compares
$156,550 in reported general payments places this provider in the 95th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 12 | $5,685 |
| MovantikNaloxegol Oxalate | 12 | $4,810 |
| Oxycodone Hcl | 50 | $857 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 68 | $831 |
| Pregabalin | 38 | $445 |
| Gabapentin | 47 | $442 |
| Cyclobenzaprine Hcl | 64 | $262 |
| EndocetOxycodone Hcl/Acetaminophen | 11 | $135 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $128 |
| Tizanidine Hcl | 19 | $111 |
| Tramadol Hcl | 20 | $89 |
| Meloxicam | 19 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $25 | $4,81012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 82 interventional pain medicine providers in New Jersey.
Other interventional pain medicine in Edgewater
- Youssef JosephsonWest Deptford$496K
- Ali ValimahomedHolmdel$415K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Steve AydinFranklin Lakes$22K
- Kieran SlevinHainesport$21K
- John CoccaroToms River$17K
- Dinash YanamadulaLawrenceville$16K
- Jay ShahColonia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.